- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.07. | Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress | 1 | Investing.com | ||
| 02.07. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.07. | Belite Bio, Inc: Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy | 82 | GlobeNewswire (Europe) | - 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc.... ► Artikel lesen | |
| 27.05. | Belite Bio auf dem Stifel Forum: Strategische Arzneimittelentwicklungen | 1 | Investing.com Deutsch | ||
| 22.05. | Belite Bio-Aktie hält 80 US-Dollar-Kursziel nach FDA-Durchbruchsstatus | 1 | Investing.com Deutsch | ||
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| 22.05. | Belite Bio stock holds $80 target on FDA breakthrough nod | 3 | Investing.com | ||
| 21.05. | Belite Bio gets FDA breakthrough therapy status for Stargardt disease treatment | 1 | Seeking Alpha | ||
| 21.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.05. | Belite Bio Reports Breakthrough Therapy Designation For Tinlarebant | 1 | RTTNews | ||
| 21.05. | Belite Bio, Inc: Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease | 220 | GlobeNewswire (Europe) | Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant's efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a... ► Artikel lesen | |
| 15.05. | Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged | 1 | Investing.com | ||
| 15.05. | Belite Bio stock retains Overweight rating at Cantor Fitzgerald | 1 | Investing.com | ||
| 15.05. | Belite Bio signals positive DSMB review and targets 500-patient PHOENIX trial enrollment completion in Q3 2025 while maintaining strong cash runway | 5 | Seeking Alpha | ||
| 14.05. | Belite Bio GAAP EPS of -$0.27 beats by $0.08 | 1 | Seeking Alpha | ||
| 14.05. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.05. | Belite Bio, Inc: Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update | 121 | GlobeNewswire (Europe) | Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1)... ► Artikel lesen | |
| 29.04. | Belite Bio, Inc: Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 15.04. | BELITE BIO, INC - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 26.03. | Belite Bio stock target raised to $80 at Benchmark | 1 | Investing.com | ||
| 21.03. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 0,446 | +3,03 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| ARGENX | 480,80 | -1,05 % | $1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 1,290 | +3,20 % | Protalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer | CARMIEL, Israel, July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production... ► Artikel lesen | |
| ENZO BIOCHEM | 0,580 | 0,00 % | Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction | Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June 24, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc.... ► Artikel lesen | |
| QUANTERIX | 5,340 | -0,37 % | Quanterix entlässt Führungskräfte bei Akoya-Tochter und rechnet mit Kosten von 3,3 Millionen US-Dollar | ||
| LEXEO THERAPEUTICS | 4,210 | +0,96 % | Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights | Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned... ► Artikel lesen | |
| EVOTEC | 6,170 | -17,25 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,970 | +19,25 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| QIAGEN | 40,885 | -1,26 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 58,50 | +4,46 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| BIONTECH | 94,75 | +0,37 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| SAB BIOTHERAPEUTICS | 4,270 | +51,96 % | SAB Biotherapeutics sichert sich 175 Mio. US-Dollar über Privatplatzierung - Aktie legt um 33 % zu | ||
| SIONNA THERAPEUTICS | 16,740 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports First Quarter 2025 Financial Results | Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,670 | +2,76 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen |
Das Unternehmen BELITE BIO INC ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,00 (0,00 %) liegt der Kurs bei 51,50 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.